---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-074426"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T23:00:56.275362+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences presents one-year IGNITE DMD data; SGT-001 program concluded

## Summary
- One-year data: mean 69.8% normal dystrophin by Western blot in 2E14 vg/kg cohort (Pt.5 at 18 months).
- Motor function: 6MWT and NSAA showed positive mean change from baseline at 1 year.
- Pulmonary function: FVC % predicted and FEV1 % predicted improved from baseline.
- Safety: 2/9 SAEs related to SGT-001 (thrombocytopenia, hepatotoxicity, systemic inflammatory response).
- SGT-001 program concluded; next-gen SGT-003 with novel capsid in IND-enabling studies.

## SEC filing metadata
- accession: 0001193125-23-074426
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312523074426/0001193125-23-074426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312523074426/d487716d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-074426
- JSON: https://secwatch.observer/filing/0001193125-23-074426.json
- Plain text: https://secwatch.observer/filing/0001193125-23-074426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.